ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.29
-1.08%
US Tech 100
20,742.80
-0.76%
S&P 500
5,935.25
-0.60%
US Dollar vs CAD
1.4354
-0.35%
Bitcoin
94,482.32
1.03%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Valneva Se (0OB3)

  7. Valneva Se (0OB3) News

0OB3

Valneva (0OB3)

Valneva Se
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0OB3
DateTimeSourceHeadlineSymbolCompany
12/19/20241:00AMUK RegulatoryValneva accroît l’accessibilité de son vaccin contre le chikungunya en Asie grâce à une collaboration avec le Serum Institute of IndiaLSE:0OB3Valneva Se
12/19/20241:00AMUK RegulatoryValneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of IndiaLSE:0OB3Valneva Se
12/05/202412:30AMUK RegulatoryVALNEVA - Declaration of shares and voting rights: November 30, 2024LSE:0OB3Valneva Se
12/05/202412:30AMUK RegulatoryDéclaration d'actions et de droits de vote de la société Valneva SE - novembre 2024LSE:0OB3Valneva Se
12/04/202412:00AMUK RegulatoryValneva annonce la publication dans le British Medical Journal d’un article sur l’impact sanitaire et économique mondial du chikungunyaLSE:0OB3Valneva Se
12/04/202412:00AMUK RegulatoryValneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical JournalLSE:0OB3Valneva Se
12/03/202412:00AMUK RegulatoryValneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®LSE:0OB3Valneva Se
12/03/202412:00AMUK RegulatoryValneva annonce des données positives sur la persistance des anticorps à trois ans pour son vaccin à dose unique contre le chikungunya, IXCHIQ®LSE:0OB3Valneva Se
11/26/202410:45AMUK RegulatoryValneva soumet à la FDA une demande d’extension d’indication pour son vaccin contre le chikungunya IXCHIQ®LSE:0OB3Valneva Se
11/26/202410:45AMUK RegulatoryValneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDALSE:0OB3Valneva Se
11/13/202410:45AMUK RegulatoryValneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2LSE:0OB3Valneva Se
11/13/202410:45AMUK RegulatoryValneva et LimmaTech annoncent la vaccination du premier participant à l’essai d’infection contrôlée de Phase 2b du candidat vaccin tétravalent contre la shigellose S4V2LSE:0OB3Valneva Se
11/12/202412:00AMUK RegulatoryValneva fera des présentations et rencontrera les investisseurs lors de conférences aux États-Unis et en EuropeLSE:0OB3Valneva Se
11/12/202412:00AMUK RegulatoryValneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare ConferencesLSE:0OB3Valneva Se
11/07/202412:00AMUK RegulatoryValneva publie ses résultats financiers pour les neuf premiers mois de l’exercice 2024 et fait un point sur ses activitésLSE:0OB3Valneva Se
11/07/202412:00AMUK RegulatoryValneva Reports Nine-Month 2024 Financial Results and Provides Corporate UpdatesLSE:0OB3Valneva Se
11/06/20241:30AMUK RegulatoryVALNEVA - Declaration of shares and voting rights: October 31, 2024LSE:0OB3Valneva Se
11/06/20241:30AMUK RegulatoryVALNEVA - Déclaration d’actions et de droits de vote : 31 octobre 2024LSE:0OB3Valneva Se
10/21/202410:45AMUK RegulatoryValneva effectuera des présentations sur le chikungunya lors de différentes conférences scientifiques de premier planLSE:0OB3Valneva Se
10/21/202410:45AMUK RegulatoryValneva to Present on Chikungunya at Several Leading Scientific ConferencesLSE:0OB3Valneva Se
10/16/202410:45AMUK RegulatoryValneva and LimmaTech reçoivent le statut « Fast Track » de la FDA pour leur candidat vaccin tétravalent contre la Shigellose S4VLSE:0OB3Valneva Se
10/16/202410:45AMUK RegulatoryValneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4VLSE:0OB3Valneva Se
10/10/202412:00AMUK RegulatoryValneva Hosts Investor Day in New York CityLSE:0OB3Valneva Se
10/10/202412:00AMUK RegulatoryValneva organise une journée investisseurs aujourd’hui à New YorkLSE:0OB3Valneva Se
10/04/202412:30AMUK RegulatoryValneva SE - Déclaration d’actions et de droits de vote - 30 septembre 2024LSE:0OB3Valneva Se
10/04/202412:30AMUK RegulatoryValneva SE - Declaration of shares and voting rights - September 30, 2024LSE:0OB3Valneva Se
10/03/202412:00AMUK RegulatoryValneva organise une journée investisseurs à New York le 10 octobre 2024LSE:0OB3Valneva Se
10/03/202412:00AMUK RegulatoryValneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ETLSE:0OB3Valneva Se
09/18/202412:00AMUK RegulatoryValneva soumet des demandes d’élargissement de l’indication de son vaccin contre le chikungunya IXCHIQ® à l’EMA et Santé CanadaLSE:0OB3Valneva Se
09/18/202412:00AMUK RegulatoryValneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health CanadaLSE:0OB3Valneva Se
 Showing the most relevant articles for your search:LSE:0OB3

Your Recent History

AQSE
KING
Igraine
BIT
SFT
Softlab
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads